SpectraCure AB Total Liabilities
SpectraCure AB total liabilities. Based on the latest financial reports, SpectraCure AB (SPEC) has total liabilities worth Skr10.92 Million SEK (≈ $1.17 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SpectraCure AB (SPEC) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SpectraCure AB (2013–2025)
Total liabilities of SpectraCure AB from 2013 to 2025. This chart illustrates how SpectraCure AB's total liabilities have evolved over time, based on quarterly financial data.
SpectraCure AB Competitors by Total Liabilities
The table below lists competitors of SpectraCure AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lilium NV
NASDAQ:LILM
|
USA | $280.49 Million |
|
M.T.I Wireless Edge Ltd
LSE:MWE
|
UK | GBX16.56 Million |
|
MEMIONTEC HOLDINGS LTD
F:8900
|
Germany | €25.07 Million |
|
Cell Impact AB
ST:CI
|
Sweden | Skr29.21 Million |
|
IMAGE POWER S.A. ZY -10
F:7UQ
|
Germany | €280.97K |
|
Infinitum Copper Corp
V:INFI
|
Canada | CA$757.67K |
|
Panthera Resources PLC
LSE:PAT
|
UK | GBX1.06 Million |
|
Fort St James Nickel Corp
V:FTJ
|
Canada | CA$2.11 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down SpectraCure AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SPEC total assets.
Liquidity & Leverage Metrics
SpectraCure AB Total Liabilities Ratios Explained
SpectraCure AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.27 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SpectraCure AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SpectraCure AB (2013–2025)
The table below shows the annual total liabilities of SpectraCure AB from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr10.92 Million ≈ $1.17 Million |
-22.83% |
| 2024-12-31 | Skr14.15 Million ≈ $1.52 Million |
-5.53% |
| 2023-12-31 | Skr14.97 Million ≈ $1.61 Million |
+23.56% |
| 2022-12-31 | Skr12.12 Million ≈ $1.30 Million |
-18.33% |
| 2021-12-31 | Skr14.84 Million ≈ $1.60 Million |
+11.42% |
| 2020-12-31 | Skr13.32 Million ≈ $1.43 Million |
+7.31% |
| 2019-12-31 | Skr12.41 Million ≈ $1.34 Million |
+208.01% |
| 2018-12-31 | Skr4.03 Million ≈ $433.69K |
+209.74% |
| 2017-12-31 | Skr1.30 Million ≈ $140.02K |
-80.46% |
| 2016-12-31 | Skr6.66 Million ≈ $716.59K |
+542.83% |
| 2015-12-31 | Skr1.04 Million ≈ $111.47K |
-88.04% |
| 2014-12-31 | Skr8.66 Million ≈ $932.40K |
+269.23% |
| 2013-12-31 | Skr2.35 Million ≈ $252.53K |
-- |
About SpectraCure AB
SpectraCure AB (publ) engages in the development of cancer treatment system in Sweden. It develops Q-PRO, a laser unit; IDOSE software platform, which calculates the optimal laser light dose and placement of the optical fibers; and disposable items comprising needles, optical fibers, and light-sensitive medication. The company was incorporated in 2003 and is based in Lund, Sweden.